Back to results
US 2024/0002803 A1Published application
Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
AssigneeSuperMeat the Essence of Meat Ltd.
InventorsIdo SAVIR, Tomer HALEVY, Yuval LEVY PERETZ
Life of this patent
Estimating the term…
Abstract
Primed cells, pluripotent stem cell aggregates and microtissues produced therefrom and uses of same for producing edible products.
Claims21
A method of producing a microtissue comprising one or more cell types, the method comprising:
- (a) forming in suspension, without matrix adherence, aggregates comprising non-human pluripotent stem cells, said non-human pluripotent stem cells of said aggregates exhibiting a doubling time of 10-20 hours in an undifferentiated manner for more than 60 passages, capable of differentiating into muscle, fat and connective tissue upon differentiation induction, growing in the presence of growth factors, exhibiting cell to cell adhesion lower than that of embryoid bodies (EBs) as determined by reduced expression of adhesion molecules selected from the group consisting of COL6A2, CD44, COL6A1, ANXA1, ANXA2 and S100A11 as compared to said EBs;
- and
- (b) transferring the aggregates to a bioreactor for growth in suspension without matrix adherence in the absence of growth factors to thereby produce the microtissue.
A method of producing a microtissue comprising one or more cell types, the method comprising:
- (a) providing a suspension culture which comprises aggregates comprising non-human pluripotent stem cells, said non-human pluripotent stem cells of said aggregates exhibiting a doubling time of 10-20 hours in an undifferentiated manner for more than 60 passages, capable of differentiating into muscle, fat and connective tissue upon differentiation induction, growing in the presence of growth factors, exhibiting cell to cell adhesion lower than that of embryoid bodies (EBs) as determined by reduced expression of adhesion molecules selected from the group consisting of COL6A2, CD44, COL6A1, ANXA1, ANXA2 and S100A11 as compared to said EBs;
- and
- (b) transferring the aggregates to a bioreactor for growth in suspension without matrix adherence in the absence of growth factors to thereby produce the microtissue.
A microtissue comprising one or more cell types, said microtissue being 30-500 μm in diameter, wherein cells of said microtissue are NANOG-OCT4− LIN28−, SSEA3+, and wherein optionally said one or more cell types comprise a fat cell and a muscle cell.
Dependencies are inferred from the claim text.